Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemia

Olga Goronkova, Galina Novichkova, Tatiana Salimova, Irina Kalinina, Dina Baidildina, Ulyana Petrova, Kristina Antonova, Maria Sadovskaya, Elena Suntsova, Dmitry Evseev, Victor Matveev, Dmitry Venyov, Lili Khachatryan, Dmitry Litvinov, Alexey Pshonkin, Galina Ovsyannikova, Natalia Kotskaya, Darina Gobadze, Yulia Olshanskaya, Alexander Popov, Elena Raykina, Olga Mironenko, Kirill Voronin, Bazarma Purbueva, Elmira Boichenko, Yulia Dinikina, Evgeniya Guseynova, Dmitry Sherstnev, Elena Kalinina, Sergey Mezentsev, Olga Streneva, Natalia Yudina, Olga Plaksina, Elena Erega, Michael Maschan, Alexey Maschan, Olga Goronkova, Galina Novichkova, Tatiana Salimova, Irina Kalinina, Dina Baidildina, Ulyana Petrova, Kristina Antonova, Maria Sadovskaya, Elena Suntsova, Dmitry Evseev, Victor Matveev, Dmitry Venyov, Lili Khachatryan, Dmitry Litvinov, Alexey Pshonkin, Galina Ovsyannikova, Natalia Kotskaya, Darina Gobadze, Yulia Olshanskaya, Alexander Popov, Elena Raykina, Olga Mironenko, Kirill Voronin, Bazarma Purbueva, Elmira Boichenko, Yulia Dinikina, Evgeniya Guseynova, Dmitry Sherstnev, Elena Kalinina, Sergey Mezentsev, Olga Streneva, Natalia Yudina, Olga Plaksina, Elena Erega, Michael Maschan, Alexey Maschan

Abstract

We compared the efficacy and safety of eltrombopag (ELTR) combined with immunosuppressive therapy (IST) and IST alone in treatment-naïve children with severe (SAA) and very severe (vSAA) aplastic anemia. Ninety-eight pediatric patients were randomized to receive horse antithymocyte globulin (hATG) and cyclosporin A (CsA) with (n = 49) or without (n = 49) ELTR. The primary endpoint was the overall response rate (ORR) at 4 months. After 4 months, nonresponders were crossed over to the alternative group. In all patients, the ORR in ELTR + IST and IST groups was similar (65% vs 53%; P = .218); however, the complete response (CR) rate was significantly higher in the ELTR + IST group (31% vs 12%; P = .027). In severity subgroups, the ORR was 89% vs 57% (P = .028) in favor of IST + ELTR in SAA, but it did not differ in patients with vSAA (52% vs 50%; P = .902). At 6 months after the crossover, 61% of initial ELTR(-) patients achieved a response compared with 17% of initial ELTR(+) patients (P = .016). No significant difference in ELTR + IST and IST groups was observed in the 3-year overall survival (OS) (89% vs 91%; P = .673) or the 3-year event-free survival (EFS) (53% vs 41%; P = .326). There was no unexpected toxicity related to ELTR. Adding ELTR to standard IST was well tolerated and increased the CR rate. The greatest benefit from ELTR combined with IST was observed in patients with SAA but not in those with vSAA. The second course of IST resulted in a high ORR in initial ELTR(-) patients who added ELTR and had limited efficacy among patients who received ELTR upfront. This trial was registered at Clinicaltrials.gov as #NCT03413306.

Conflict of interest statement

Conflict-of-interest disclosure: A.M. received lecturer’s fees from Novartis. M.M. received lecturer’s fees from Miltenyi Biotec. The remaining authors declare no competing financial interests.

© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Figures

Graphical abstract
Graphical abstract
Figure 1.
Figure 1.
Cumulative incidence of hematologic response by treatment group and depending on theseverity ofAA. (A) Cumulative incidence of OR by treatment group. (B) Cumulative incidence of CR by treatment group. (C) Cumulative incidence of OR in SAA (ANC ≥0.2 × 109/L) patients by treatment group. (D) Cumulative incidence of OR in vSAA (ANC <0.2 × 109/L) patients by treatment group. Shaded areas are 95% CIs. Competing events included death. The start of the second-line treatment with hATG/CsA ± ELTR and HSCT was considered censoring. P values are given for the 4-month point. The cumulative incidence of the overall response at 4 months was 65% (95% CI, 52-79) in the ELTR + IST group and 54% (95% CI, 40-69) in the IST group (A). The cumulative incidences for complete response at 4 months were 31% (95% CI, 18-44) and 13% (95% CI, 3-22), respectively (B). The cumulative incidence of the overall response at 4 months in patients with SAA (ANC ≥0.2 × 109/L) was 89% (95% CI, 89-100) in the ELTR + IST group and 57% (95% CI, 35-79) in the IST group (C). The cumulative incidence of the overall response at 4 months in patients with vSAA (ANC <0.2 × 109/L) was 52% (95% CI, 34-70) and 52% (95% CI, 33-72) (D).
Figure 2.
Figure 2.
OS, EFS, and cumulative incidence of relapse of patients with SAA by treatment group.

References

    1. Young NS. Current concepts in the pathophysiology and treatment of aplastic anemia. Hematology (Am Soc Hematol Educ Program) 2013;2013:76–81.
    1. Hartung HD, Olson TS, Bessler M. Acquired aplastic anemia in children. Pediatr Clin North Am. 2013;60(6):1311–1336.
    1. Yoshida N, Kobayashi R, Yabe H, et al. First-line treatment for severe aplastic anemia in children: bone marrow transplantation from a matched family donor versus immunosuppressive therapy. Haematologica. 2014;99(12):1784–1791.
    1. Dufour C, Pillon M, Sociè G, et al. Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant. Br J Haematol. 2015;169(4):565–573.
    1. Bacigalupo A. How I treat acquired aplastic anemia. Blood. 2017;129(11):1428–1436.
    1. Scheinberg P, Wu CO, Nunez O, Young NS. Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine. J Pediatr. 2008;153(6):814–819.
    1. Gurion R, Gafter-Gvili A, Paul M, et al. Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis. Haematologica. 2009;94(5):712–719.
    1. Erickson-Miller CL, Delorme E, Tian SS, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2009;27(2):424–430.
    1. Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012;367(1):11–19.
    1. Desmond R, Townsley DM, Dumitriu B, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014;123(12):1818–1825.
    1. Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017;376(16):1540–1550.
    1. Belaya Z, Golounina O, Nikitin A, et al. Multiple bilateral hip fractures in a patient with dyskeratosis congenita caused by a novel mutation in the PARN gene. Osteoporos Int. 2021;32(6):1227–1231.
    1. Semchenkova A, Kashpor S, Verzhbitskaya T, et al. FLAER-negative CD15+ neutrophils can be used for the simplified screening of suspected PNH cases. Int J Lab Hematol. 2020;42(5):589–593.
    1. Illingworth A, Marinov I, Sutherland DR, Wagner Ballon O, Del Vecchio L. ICCS/ESCCA consensus guidelines to detect GPI deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders: part 3 – Data analysis, reporting and case studies. Cytometry B Clin Sytom. 2018;94(1):49–66.
    1. Camitta BM. Criteria for severe aplastic anaemia. Lancet. 1988;1(8580):303–304.
    1. Wire MB, Li X, Zhang J, Sallas W, Aslanis V, Ouatas T. Modeling and simulation support eltrombopag dosing in pediatric patients with immune thrombocytopenia. Clin Pharmacol Ther. 2018;104(6):1199–1207.
    1. Scheinberg P, Nunez O, Weinstein B, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011;365(5):430–438.
    1. Marsh JC, Bacigalupo A, Schrezenmeier H, et al. European Blood and Marrow Transplant Group Severe Aplastic Anaemia Working Party Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. Blood. 2012;119(23):5391–5396. [published correction appears in Blood. 2013;121(25):5104]
    1. Jeong DC, Chung NG, Cho B, et al. Long-term outcome after immunosuppressive therapy with horse or rabbit antithymocyte globulin and cyclosporine for severe aplastic anemia in children. Haematologica. 2014;99(4):664–671.
    1. Tichelli A, Schrezenmeier H, Socié G, et al. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2011;117(17):4434–4441.
    1. Zheng Y, Liu Y, Chu Y. Immunosuppressive therapy for acquired severe aplastic anemia (SAA): a prospective comparison of four different regimens. Exp Hematol. 2006;34(7):826–831.
    1. Scheinberg P, Rios O, Scheinberg P, Weinstein B, Wu CO, Young NS. Prolonged cyclosporine administration after antithymocyte globulin delays but does not prevent relapse in severe aplastic anemia. Am J Hematol. 2014;89(6):571–574.
    1. Saracco P, Quarello P, Iori AP, et al. Bone Marrow Failure Study Group of the AIEOP (Italian Association of Paediatric Haematology Oncology) Cyclosporin A response and dependence in children with acquired aplastic anaemia: a multicentre retrospective study with long-term observation follow-up. Br J Haematol. 2008;140(2):197–205.
    1. Assi R, Garcia-Manero G, Ravandi F, et al. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer. 2018;124(21):4192–4201.
    1. Groarke EM, Patel BA, Gutierrez-Rodrigues F, et al. Eltrombopag added to immunosuppression for children with treatment-naïve severe aplastic anaemia. Br J Haematol. 2021;192(3):605–614.
    1. Peffault de Latour R, Kulasekararaj A, Iacobelli S, et al. Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation Eltrombopag added to immunosuppression in severe aplastic anemia. N Engl J Med. 2022;386(1):11–23.
    1. Narita A, Muramatsu H, Sekiya Y, et al. Japan Childhood Aplastic Anemia Study Group Paroxysmal nocturnal hemoglobinuria and telomere length predicts response to immunosuppressive therapy in pediatric aplastic anemia. Haematologica. 2015;100(12):1546–1552.
    1. Kulagin A, Lisukov I, Ivanova M, et al. Prognostic value of paroxysmal nocturnal haemoglobinuria clone presence in aplastic anaemia patients treated with combined immunosuppression: results of two-centre prospective study. Br J Haematol. 2014;164(4):546–554.
    1. Imada K, Obara N, Iida H, et al. Eltrombopag in combination with rabbit antithymocyte globulin/cyclosporine A in immunosuppressive therapy-naïve patients with aplastic anemia in Japan. Intern Med. 2021;60(8):1159–1168.
    1. Dufour C, Veys P, Carraro E, et al. Similar outcome of upfront-unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of EBMT. Br J Haematol. 2015;171(4):585–594.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅